uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy
Departments of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
Departments of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm , Ludwig Institute for Cancer Research.
Departments of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska.
Show others and affiliations
2005 (English)In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 65, no 17, 7824-7831 p.Article in journal (Refereed) Published
Abstract [en]

Whereas radioimmunotherapy of hematologic malignancies has evolved into a viable treatment option, the responses of solid tumors to radioimmunotherapy are discouraging. The likely cause of this problem is the interstitial hypertension inherent to all solid tumors. Remarkable improvements in tumor responses to radioimmunotherapy were discovered after the inclusion of STI571 in the therapy regimen. A combination of the tumor stroma-reactive STI571, a potent platelet-derived growth factor receptor-beta (PDGFr-beta) antagonist, and the tumor-seeking radiolabeled antibody B72.3 yielded long-lasting growth arrest of the human colorectal adenocarcinoma LS174T grown as s.c. xenografts in athymic mice. The interaction of STI571 with the stromal PDGFr-beta reduced tumor interstitial fluid pressure (P(IF)) by >50% and in so doing improved the uptake of B72.3. The attenuation of P(IF) also had a positive effect on the homogeneity of antibody distribution. These effects were dose-dependent and under optimized dosing conditions allowed for a 2.45 times increase in the tumor uptake of B72.3 as determined in the biodistribution studies. Single-photon emission computed tomography imaging studies substantiated these results and indicated that the homogeneity of the radioisotope distribution was also much improved when compared with the control mice. The increased uptake of radioimmunotherapy into the tumor resulted in >400% increase in the tumor absorbed radiation doses in STI571 + radioimmunotherapy-treated mice compared with PBS + radioimmunotherapy-treated mice. The improved antibody uptake in response to the attenuation of tumor P(IF) was identified as the primary reason for the growth arrest of the STI571 + radioimmunotherapy-treated tumors. Two related causes were also identified: (a) the improved homogeneity of monoclonal antibody distribution in tumor and (b) the increased tumor radiosensitivity resulting from the improved tumor oxygenation.

Place, publisher, year, edition, pages
2005. Vol. 65, no 17, 7824-7831 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-144579DOI: 10.1158/0008-5472.CAN-04-3991PubMedID: 16140951OAI: oai:DiVA.org:uu-144579DiVA: diva2:393631
Available from: 2011-01-31 Created: 2011-01-31 Last updated: 2011-04-26Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Ludwig Institute for Cancer Research
In the same journal
Cancer Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 203 hits
ReferencesLink to record
Permanent link

Direct link